Related Experiment Video
Updated: Jul 19, 2026
08:05
Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
Published on: June 10, 2025
ProstaScint(R) Scan: Contemporary Use in Clinical Practice
Reviews in Urology
|September 21, 2006
Summary
Indium In 111 capromab pendetide (ProstaScint) aids in locating prostate cancer metastasis. Improved imaging techniques have enhanced its accuracy for staging, relapse detection, and new applications.
Area of Science:
- Oncology
- Nuclear Medicine
- Immunology
Background:
- Prostate cancer often metastasizes to soft tissues.
- Indium In 111 capromab pendetide is a radiolabeled monoclonal antibody targeting prostate-specific membrane antigen.
- Early limitations in ProstaScint's accuracy were due to single photon emission computed tomography (SPECT) and poor predictive value.
Purpose of the Study:
- To evaluate the diagnostic accuracy of Indium In 111 capromab pendetide for soft tissue metastasis in prostate cancer.
- To explore the evolving applications of ProstaScint beyond conventional staging and relapse detection.
Main Methods:
- Utilizing Indium In 111 capromab pendetide as a diagnostic imaging agent.
- Employing advanced anatomic localization techniques to improve image interpretation.
- Leveraging increased reader experience to enhance diagnostic specificity and positive predictive value.
Main Results:
- Significant improvements in the accuracy of ProstaScint have been achieved.
- Enhanced techniques have overcome previous limitations in positive predictive value and specificity.
- ProstaScint demonstrates potential in identifying soft tissue metastases.
Conclusions:
- Indium In 111 capromab pendetide, with improved imaging, is a valuable tool for prostate cancer management.
- Its applications extend to staging, relapse detection, and novel uses in oncology.
- Continued advancements promise to further refine its role in diagnosing prostate cancer spread.
